Lung tumor markers of cytokeratin origin: An overview

Lung Cancer

Volumn 34, Issue , 2001, Pages S65-S69

  Buccheri, Gianfranco ^a   Ferrigno, Domenico ^a  

^a S CROCE E CARLE HOSPITAL   (Italy)

Author keywords

Bronchogenic carcinoma; Cytokeratin 19 fragments; Cytokeratins; Cytoskeleton; Tissue polypeptide antigen; Tissue polypeptide specific antigen; Tumor markers

Indexed keywords

CYTOKERATIN 18; CYTOKERATIN 19; EPITOPE; STRUCTURAL PROTEIN; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKER;

ANTIGEN SPECIFICITY; CANCER CELL DESTRUCTION; CANCER DIAGNOSIS; CANCER GROWTH; CANCER STAGING; CONFERENCE PAPER; DIAGNOSTIC VALUE; HUMAN; LUNG CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; TUMOR VOLUME;

CYTOSKELETON; DISEASE PROGRESSION; HUMANS; KERATINS; LUNG NEOPLASMS; PEPTIDES; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 0035191105     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(01)00347-6     Document Type: Article

References (47)

1. Cancer of the lung
2. Tumour markers in the management of human cancer
3. Serum tumour markers in lung cancer: History, biology and clinical applications
4. Clinical applications of serum markers for lung cancer
5. Tumor markers: Clinical meaning and use
6. Cytoskeleton-plasma membrane interactions
7. Intermediate filaments as mechanical integrators of cellular space
8. Immunoistochemical distinction of human carcinomas by cytocheratin typing with monoclonal antibodies
9. Cytokeratins and tissue polypeptide antigen
10. Cytocheratins in different types of human lung cancer as monitored by chain-specific monoclonal antibodies
11. Comparison of CYFRA 21-1, TPA and TPS in lung cancer, urinary bladder cancer and benign diseases
12. Antigenicity of pooled human malignant and normal tissues by cytoimmunological technique: Presence of an insoluble, heat-labile tumor antigen
13. A human tissue polypeptide related to cancer and placenta: I. preparation and properties, II. assay technique, III. clinical studies of 1483 individuals with cancer and other conditions
14. Sequence homology between tissue polypeptide antigen (TPA) and intermediate filament (IF) proteins
15. Cytokeratins as serum markers in lung cancer: A comparison of CYFRA 21-1 and TPS
16. Clinical evaluation of serum tissue polypeptide-specific antigen (TPS) in non-small cell lung cancer
17. Technical evaluation of a new automated tumor marker assay: The Enzymun-Test CYFRA 21-1
18. Demonstration of tumor-specific antigenin in human colonic carcinomata by immunological toleramce and absorption techniques
19. Clinical utility of tissue polypeptide antigen determination in lung cancer management
20. Clinical profile of a new monoclonal antibody-based immunoassay for tissue polypeptide antigen
21. Clinical value of CYFRA 21.1, carcinoembryonic antigen, neurone-specific enolase, tissue polypeptide specific antigen and tissue polypeptide antigen in the diagnosis of lung cancer
22. Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA-TP CEA, and NSE
23. Prognostic factors in lung cancer: Tables and comments
24. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer
25. Clinical value of a multiple biomarker assay in patients with bronchogenic carcinoma
26. Tumor markers in bronchogenic carcinoma: Superiority of tissue polyptide antigen to carcinoembryonic antigen and carbohydrate antigenic determinant 19-9
27. Usefulness of tissue polypeptide antigen in staging, monitoring, and prognosis of lung cancer
28. Prognostic value of the tissue polyptide antigen in lung cancer
29. The tissue polypeptide antigen serum test in the preoperative evaluation of non-small cell lung cancer: Diagnostic yield and comparison with conventional staging methods
30. Monitoring lung cancer with tissue polyptide antigen: An ancillary, profitable serum test to evaluate treatment response and posttreatment disease status
31. Tissue polypeptide specific antigen (tps) and cytokeratin 19 fragment (CYFRA 21.1) immunoradiometric assay in non small cell lung cancer evaluation
32. Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma - Does the combined use of cytokeratin markers give any additional information
33. Prognostic significance of tissue polypeptide-specific antigen (TPS) in patients with advanced non-small cell lung cancer
34. Evaluation of the serum markers CEA, NSE, TPS and CYFRA 21.1 in lung cancer
35. Predictive factors of tumor response and prognostic factors of survival during lung cancer chemotherapy
36. Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer
37. Disease monitoring by the tumour markers Cyfra 21.1 and TPA in patients with non-small cell lung cancer
38. CYFRA 21-1: A new marker in lung cancer
39. CYFRA 21-1, a sensitive and specific new tumour marker for squamous cell lung cancer. Report of the first European multicentre evaluation
40. Assessment of serum CYFRA 21-1 in lung cancer
41. Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay
42. Diagnostic and prognostic value of the new tumour marker CIFRA 21-1 in patients with squamous cell lung cancer
43. Preoperative CYFRA 21-1 level as a prognostic indicator in resected primary squamous cell lung cancer
44. Preoperative CYFRA 21-1 level as a prognostic indicator in resected nonsmall cell lung cancer
45. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma
46. Correlation between serum cytokeratin 19 fragments and tissue polypeptide antigen levels in patients with non-small cell lung cancer
47. Pre-treatment evaluation of non-small-cell lung cancer